GlassScriptPhysician profile
Karim W Bitar
NPI 1609032523
$3,854.28
in general payments reported to CMS, 2019-2025
22 companies · $316 in 2025
The $316 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,880 · 2020: $375 · 2021: $368 · 2022: $43.70 · 2023: $522 · 2024: $350 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,694.88 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $751.85 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $225.80 | 2019-2025 | Jynarque |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $158.22 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $150.47 | 2020-2025 | Terlivaz, Acthar |
| Amgen INC. | $106.62 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Glaxosmithkline, LLC. | $105.55 | 2021-2025 | Benlysta, Shingrix, Arexvy |
| Akebia Therapeutics INC | $97.26 | 2020-2022 | |
| Fresenius USA Marketing, INC. | $78.59 | 2019-2024 | Velphoro |
| Alexion Pharmaceuticals, INC. | $74.90 | 2019-2023 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.55 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $58.10 | 2023-2025 | |
| Horizon Therapeutics Plc | $50.02 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $44.04 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.63 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $34.79 | 2024-2025 | Ibsrela |
| Nxstage Medical, INC. | $26.62 | 2020 | |
| Novo Nordisk INC | $21.10 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $20.20 | 2023 | |
| Scpharmaceuticals INC. | $16.89 | 2025 | |
| Calliditas Therapeutics US INC. | $14.55 | 2024 | |
| Amag Pharmaceuticals, INC. | $13.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Bitar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.